1 2708 111 EXERCISE IN NEUROMUSCULAR DISORDERS: A PROMISING INTERVENTION. ALTHOUGH PERFORMING EXERCISE STUDIES IN PATIENTS WITH NEUROMUSCULAR DISORDERS (NMD) IS DIFFICULT, THE NUMBER OF RANDOMIZED CONTROLLED TRIALS IS STEADILY INCREASING. THERE IS GROWING EVIDENCE FOR A POSITIVE EFFECT OF AEROBIC EXERCISE IN SEVERAL NMD, ON THE OTHER HAND, THE EVIDENCE FOR THE EFFECT OF STRENGTH TRAINING IS STILL SCARCE. MANY NMD PATIENTS ARE CAPTURED IN A VICIOUS CIRCLE OF PHYSICAL INACTIVITY, AND IT IS IMPORTANT TO LET PATIENTS ADHERE TO AN ACTIVE LIFESTYLE, IN ORDER TO PREVENT FURTHER CHRONIC CARDIOVASCULAR AND MUSCLE DECONDITIONING AND INCREASED CARDIOVASCULAR HEALTH RISKS. EXERCISE HAS TO BE PRESCRIBED AS IF IT IS MEDICINE, IN ORDER TO INCREASE THE ADHERENCE OF PATIENTS AND TO OPTIMIZE THE EFFICACY OF THE INTERVENTION. EXERCISE IN NMD IS SAFE, ALTHOUGH FOR SOME METABOLIC MYOPATHIES THERE IS A CONTRAINDICATION FOR STRENUOUS EXERCISE. IN NMD KNOWN TO AFFECT CARDIAC MUSCLE, IT IS USUALLY SAFE TO EXERCISE, BUT THE CONSULTATION OF A CARDIOLOGIST IS ADVISED. BASED ON RECENT RESEARCH, AN INCREASE IN PHYSICAL ACTIVITY OF MODERATE INTENSITY AND OF SUFFICIENT DURATION, I.E. A PHYSICALLY ACTIVE LIFESTYLE, COULD BE AT LEAST AS EFFECTIVE AND RELEVANT AS PHYSICAL TRAINING. UNDERLYING MECHANISMS OF EFFECT OF EXERCISE COULD BE THE INFLUENCE OF EPIGENETIC MECHANISMS AND THE ANTI-INFLAMMATORY EFFECT OF EXERCISE, BUT FURTHER STUDIES ARE NEEDED TO CONFIRM THESE HYPOTHESES. 2019 2 6419 16 THE TET2-UPF1 COMPLEX MODULATES MRNA STABILITY UNDER STRESS CONDITIONS. INTRODUCTION: ENVIRONMENTAL STRESS PROMOTES EPIGENETIC ALTERATIONS THAT IMPACT GENE EXPRESSION AND SUBSEQUENTLY PARTICIPATE IN THE PATHOLOGICAL PROCESSES OF THE DISORDER. AMONG EPIGENETIC REGULATIONS, TEN-ELEVEN TRANSLOCATION (TET) ENZYMES OXIDIZE 5-METHYLCYTOSINE (5MC) TO 5-HYDROXYMETHYLCYTOSINE (5HMC) IN DNA AND RNA AND FUNCTION AS CRITICAL PLAYERS IN THE PATHOGENESIS OF DISEASES. OUR PREVIOUS RESULTS SHOWED THAT CHRONIC STRESS INCREASES THE EXPRESSION OF CYTOPLASMIC TET2 IN THE HIPPOCAMPUS OF MICE EXPOSED TO CHRONIC MILD STRESS (CMS). WHETHER THE CYTOPLASMIC TET2 ALTERS RNA 5HMC MODIFICATION IN CHRONIC STRESS-RELATED PROCESSES REMAINS LARGELY UNKNOWN. METHODS: TO EXPLORE THE ROLE OF CYTOPLASMIC TET2 UNDER CMS CONDITIONS, WE ESTABLISHED CMS MICE MODEL AND DETECTED THE EXPRESSION OF RNA 5HMC BY DOT BLOT. WE VERIFIED THE INTERACTION OF TET2 AND ITS INTERACTING PROTEIN BY CO-IMMUNOPRECIPITATION COMBINED WITH MASS SPECTROMETRY AND SCREENED DOWNSTREAM TARGET GENES BY CLUSTER ANALYSIS OF TET2 AND UPSTREAM FRAMESHIFT 1 (UPF1) INTERACTING RNA. THE EXPRESSION OF PROTEIN WAS DETECTED BY WESTERN BLOT AND THE EXPRESSION OF THE SCREENED TARGET GENES WAS DETECTED BY QRT-PCR. RESULTS: IN THIS STUDY, WE FOUND THAT INCREASED CYTOPLASMIC TET2 EXPRESSION UNDER CMS CONDITIONS LEADS TO INCREASE IN TOTAL RNA 5HMC MODIFICATION. TET2 INTERACTED WITH THE KEY NON-SENSE-MEDIATED MRNA DECAY (NMD) FACTOR UPF1, REGULATED THE STABILITY OF STRESS-RELATED GENES SUCH AS UNC5B MRNA, AND MIGHT THEREBY AFFECT NEURODEVELOPMENT. DISCUSSION: IN SUMMARY, THIS STUDY REVEALED THAT TET2-MEDIATED RNA 5HMC MODIFICATION IS INVOLVED IN STRESS-RELATED MRNA STABILITY REGULATION AND MAY SERVE AS A POTENTIAL THERAPEUTIC TARGET FOR CHRONIC STRESS-RELATED DISEASES SUCH AS DEPRESSION. 2023 3 1733 22 E-CADHERIN GENE RE-EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS BY HDAC INHIBITORS. BACKGROUND: THE TUMOR SUPPRESSOR GENE E-CADHERIN GENE IS FREQUENTLY SILENCED IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS AND RESULTS IN WNT-PATHWAY ACTIVATION. WE ANALYZED THE ROLE OF HISTONE EPIGENETIC MODIFICATIONS IN E-CADHERIN GENE SILENCING. METHODS: CLL SPECIMENS WERE TREATED WITH HISTONE DEACETYLASE INHIBITOR (HDACI) MS-275 AND ANALYZED FOR E-CADHERIN EXPRESSION WITH WESTERN BLOT AND RT-PCR ANALYSIS. THE DOWNSTREAM EFFECTS OF HDACI TREATED LEUKEMIC CELLS WERE STUDIED BY ANALYZING THE EFFECT ON WNT-PATHWAY SIGNALING. HDACI INDUCED ALTERATIONS IN E-CADHERIN SPLICING WERE INVESTIGATED BY TRANSCRIPT SPECIFIC REAL TIME PCR ANALYSIS. RESULTS: TREATMENT OF CLL SPECIMENS WITH HISTONE DEACETYLASE INHIBITORS (HDACI) TREATMENT RESULTED IN AN INCREASE OF THE E-CADHERIN RNA TRANSCRIPT (5 TO 119 FOLD INCREASE, N=10) IN EIGHT OUT OF TEN CLL SPECIMENS INDICATING THAT THIS GENE IS DOWN REGULATED BY HISTONE HYPOACETYLATION IN A MAJORITY OF CLL SPECIMENS. THE E-CADHERIN RE-EXPRESSION IN CLL SPECIMENS WAS NOTED BY WESTERN BLOT ANALYSIS AS WELL. BESIDES EPIGENETIC SILENCING ANOTHER MECHANISM OF E-CADHERIN INACTIVATION IS ABERRANT EXON 11 SPLICING RESULTING IN AN ALTERNATIVELY SPLICED TRANSCRIPT THAT LACKS EXON 11 AND IS DEGRADED BY THE NON-SENSE MEDIATED DECAY (NMD) PATHWAY. OUR CHROMATIN IMMUNOPRECIPITATION EXPERIMENTS SHOW THAT HDACI INCREASED THE ACETYLATION OF HISTONES H3 AND H4 IN THE E-CADHERIN PROMOTER REGION. THIS ALSO AFFECTED THE E-CADHERIN EXON 11 SPLICING PATTERN AS HDACI TREATED CLL SPECIMENS PREFERENTIALLY EXPRESSED THE CORRECTLY SPLICED TRANSCRIPT AND NOT THE EXON 11 SKIPPED ABERRANT TRANSCRIPT. THE RE-EXPRESSED E- CADHERIN BINDS TO BETA-CATENIN WITH INHIBITION OF THE ACTIVE WNT-BETA-CATENIN PATHWAY IN THESE CELLS. THIS RESULTED IN A DOWN REGULATION OF TWO WNT TARGET GENES, LEF AND CYCLIND1 AND THE WNT PATHWAY REPORTER. CONCLUSION: THE E-CADHERIN GENE IS EPIGENETICALLY MODIFIED AND HYPOACETYLATED IN CLL LEUKEMIC CELLS. TREATMENT OF CLL SPECIMENS WITH HDACI MS-275 ACTIVATES TRANSCRIPTION FROM THIS SILENT GENE WITH EXPRESSION OF MORE CORRECTLY SPLICED E-CADHERIN TRANSCRIPTS AS COMPARED TO THE ABERRANT EXON11 SKIPPED TRANSCRIPTS THAT IN TURN INHIBITS THE WNT SIGNALING PATHWAY. THE DATA HIGHLIGHTS THE ROLE OF EPIGENETIC MODIFICATIONS IN ALTERING GENE SPLICING PATTERNS. 2013 4 4699 16 NFATC2-DEPENDENT EPIGENETIC UPREGULATION OF CXCL14 IS INVOLVED IN THE DEVELOPMENT OF NEUROPATHIC PAIN INDUCED BY PACLITAXEL. BACKGROUND: THE MAJOR DOSE-LIMITING TOXICITY OF PACLITAXEL, ONE OF THE MOST COMMONLY USED DRUGS TO TREAT SOLID TUMOR, IS PAINFUL NEUROPATHY. HOWEVER, THE MOLECULAR MECHANISMS UNDERLYING PACLITAXEL-INDUCED PAINFUL NEUROPATHY ARE LARGELY UNCLARIFIED. METHODS: PAW WITHDRAWAL THRESHOLD WAS MEASURED IN THE RATS FOLLOWING INTRAPERITONEAL INJECTION OF PACLITAXEL. THE QPCR, WESTERN BLOTTING, PROTEIN OR CHROMATIN IMMUNOPRECIPITATION, CHIP-SEQ IDENTIFICATION OF NFATC2 BINDING SITES, AND MICROARRAY ANALYSIS WERE PERFORMED TO EXPLORE THE MOLECULAR MECHANISM. RESULTS: WE FOUND THAT PACLITAXEL TREATMENT INCREASED THE NUCLEAR EXPRESSION OF NFATC2 IN THE SPINAL DORSAL HORN, AND KNOCKDOWN OF NFATC2 WITH NFATC2 SIRNA SIGNIFICANTLY ATTENUATED THE MECHANICAL ALLODYNIA INDUCED BY PACLITAXEL. FURTHER BINDING SITE ANALYSIS UTILIZING CHIP-SEQ ASSAY COMBINING WITH GENE EXPRESSION PROFILE REVEALED A SHIFT OF NFATC2 BINDING SITE CLOSER TO TTS OF TARGET GENES IN DORSAL HORN AFTER PACLITAXEL TREATMENT. WE FURTHER FOUND THAT NFATC2 OCCUPANCY MAY DIRECTLY UPREGULATE THE CHEMOKINE CXCL14 EXPRESSION IN DORSAL HORN, WHICH WAS MEDIATED BY ENHANCED INTERACTION BETWEEN NFATC2 AND P300 AND CONSEQUENTLY INCREASED ACETYLATION OF HISTONE H4 IN CXCL14 PROMOTER REGION. ALSO, KNOCKDOWN OF CXCL14 IN DORSAL HORN SIGNIFICANTLY ATTENUATED MECHANICAL ALLODYNIA INDUCED BY PACLITAXEL. CONCLUSION: THESE RESULTS SUGGESTED THAT ENHANCED INTERACTION BETWEEN P300 AND NFATC2 MEDIATED THE EPIGENETIC UPREGULATION OF CXCL14 IN THE SPINAL DORSAL HORN, WHICH CONTRIBUTED TO THE CHEMOTHERAPEUTIC PACLITAXEL-INDUCED CHRONIC PAIN. 2020 5 2326 15 EPIGENETIC REGULATION OF HOTAIR IN ADVANCED CHRONIC MYELOID LEUKEMIA. PURPOSE: CHRONIC MYELOID LEUKEMIA (CML) ACCOUNTS FOR ~10% OF LEUKEMIA CASES, AND ITS PROGRESSION INVOLVES EPIGENETIC GENE REGULATION. THIS STUDY INVESTIGATED EPIGENETIC REGULATION OF HOTAIR AND ITS TARGET MICRORNA, MIR-143, IN ADVANCED CML. PATIENTS AND METHODS: WE FIRST ISOLATED BONE MARROW MONONUCLEAR CELLS FROM 70 PATIENTS WITH DIFFERENT PHASES OF CML AND FROM HEALTHY DONORS AS NORMAL CONTROL; WE ALSO CULTURED K562 AND KCL22 CELLS, TREATED WITH DEMETHYLATION DRUG; MTT ASSAY, FLOW CYTOMETRY, QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (QPCR), METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION (MSP), WESTERN BLOT, LUCIFERASE ASSAY, RNA PULL-DOWN ASSAY AND RNA-BINDING PROTEIN IMMUNOPRECIPITATION (RIP) ASSAY WERE PERFORMED. RESULT: AS MEASURED BY QPCR, HOTAIR EXPRESSION IN K562 CELLS, KCL22 CELLS, AND SAMPLES FROM CASES OF ADVANCED-STAGE CML INCREASED WITH LEVELS OF SEVERAL DNA METHYLTRANSFERASES AND HISTONE DEACETYLATES, INCLUDING DNMT1, DNMT3A, HDAC1, EZH2, AND LSD1, AND MIR-143 LEVELS WERE DECREASED AND HOTAIR LEVELS WERE INCREASED. TREATMENT WITH 5-AZACYTIDINE, A DNA METHYLATION INHIBITOR, DECREASED DNMT1, DNMT3A, HDAC1, EZH2, LSD1 MRNA, PROTEIN LEVELS, AND HOTAIR MRNA LEVELS BUT INCREASED MIR-143 LEVELS. HOTAIR KNOCKDOWN AND MIR-143 OVEREXPRESSION BOTH INHIBITED PROLIFERATION AND PROMOTED APOPTOSIS IN KCL22 AND K562 CELLS THROUGH THE PI3K/AKT PATHWAY. RNA PULL-DOWN, MASS SPECTROMETRY, AND RIP ASSAYS SHOWED THAT HOTAIR INTERACTED WITH EZH2 AND LSD1. A DUAL-LUCIFERASE ASSAY DEMONSTRATED THAT HOTAIR INTERACTED WITH MIR-143. CONCLUSION: OUR FINDINGS DEMONSTRATE THE KEY EPIGENETIC INTERACTIONS OF HOTAIR RELATED TO CML PROGRESSION AND SUGGEST HOTAIR AS A POTENTIAL THERAPEUTIC TARGET FOR ADVANCED CML. FURTHERMORE, OUR RESULTS SUPPORT THE USE OF DEMETHYLATION DRUGS AS A CML TREATMENT STRATEGY. 2018 6 3433 19 HYDROXYMETHYLATION OF MICRORNA-365-3P REGULATES NOCICEPTIVE BEHAVIORS VIA KCNH2. DNA 5-HYDROXYLMETHYLCYTOSINE (5HMC) CATALYZED BY TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE (TET) OCCURS ABUNDANTLY IN NEURONS OF MAMMALS. HOWEVER, THE IN VIVO CAUSAL LINK BETWEEN TET DYSREGULATION AND NOCICEPTIVE MODULATION HAS NOT BEEN ESTABLISHED. HERE, WE FOUND THAT SPINAL TET1 AND TET3 WERE SIGNIFICANTLY INCREASED IN THE MODEL OF FORMALIN-INDUCED ACUTE INFLAMMATORY PAIN, WHICH WAS ACCOMPANIED WITH THE AUGMENT OF GENOME-WIDE 5HMC CONTENT IN SPINAL CORD. KNOCKDOWN OF SPINAL TET1 OR TET3 ALLEVIATED THE FORMALIN-INDUCED NOCICEPTIVE BEHAVIOR AND OVEREXPRESSION OF SPINAL TET1 OR TET3 IN NAIVE MICE PRODUCED PAIN-LIKE BEHAVIOR AS EVIDENCED BY DECREASED THERMAL PAIN THRESHOLD. FURTHERMORE, WE FOUND THAT TET1 OR TET3 REGULATED THE NOCICEPTIVE BEHAVIOR BY TARGETING MICRORNA-365-3P (MIR-365-3P). FORMALIN INCREASED 5HMC IN THE MIR-365-3P PROMOTER, WHICH WAS INHIBITED BY KNOCKDOWN OF TET1 OR TET3 AND MIMICKED BY OVEREXPRESSION OF TET1 OR TET3 IN NAIVE MICE. NOCICEPTIVE BEHAVIOR INDUCED BY FORMALIN OR OVEREXPRESSION OF SPINAL TET1 OR TET3 COULD BE PREVENTED BY DOWNREGULATION OF MIR-365-3P, AND MIMICKED BY OVEREXPRESSION OF SPINAL MIR-365-3P. FINALLY, WE DEMONSTRATED THAT A POTASSIUM CHANNEL, VOLTAGE-GATED EAG-RELATED SUBFAMILY H MEMBER 2 (KCNH2), VALIDATED AS A TARGET OF MIR-365-3P, PLAYED A CRITICAL ROLE IN NOCICEPTIVE MODULATION BY SPINAL TET OR MIR-365-3P. TOGETHER, WE CONCLUDED THAT TET-MEDIATED HYDROXYMETHYLATION OF MIR-365-3P REGULATES NOCICEPTIVE BEHAVIOR VIA KCNH2. SIGNIFICANCE STATEMENT: MOUNTING EVIDENCE INDICATES THAT EPIGENETIC MODIFICATIONS IN THE NOCICEPTIVE PATHWAY CONTRIBUTE TO PAIN PROCESSES AND ANALGESIA RESPONSE. HERE, WE FOUND THAT THE INCREASE OF 5HMC CONTENT MEDIATED BY TET1 OR TET3 IN MIR-365-3P PROMOTER IN THE SPINAL CORD IS INVOLVED IN NOCICEPTIVE MODULATION THROUGH TARGETING A POTASSIUM CHANNEL, KCNH2. OUR STUDY REVEALS A NEW EPIGENETIC MECHANISM UNDERLYING NOCICEPTIVE INFORMATION PROCESSING, WHICH MAY BE A NOVEL TARGET FOR DEVELOPMENT OF ANTINOCICEPTIVE DRUGS. 2016 7 2452 19 EPIGENETIC SUPPRESSION OF POTASSIUM-CHLORIDE CO-TRANSPORTER 2 EXPRESSION IN INFLAMMATORY PAIN INDUCED BY COMPLETE FREUND'S ADJUVANT (CFA). BACKGROUND: MULTIPLE MECHANISMS CONTRIBUTE TO THE STIMULUS-EVOKED PAIN HYPERSENSITIVITY THAT MAY BE EXPERIENCED AFTER PERIPHERAL INFLAMMATION. PERSISTENT PATHOLOGICAL STIMULI IN MANY PAIN CONDITIONS AFFECT THE EXPRESSION OF CERTAIN GENES THROUGH EPIGENETIC ALTERNATIONS. THE MAIN PURPOSE OF OUR STUDY WAS TO INVESTIGATE THE ROLE OF EPIGENETIC MODIFICATION ON POTASSIUM-CHLORIDE CO-TRANSPORTER 2 (KCC2) GENE EXPRESSION IN THE PERSISTENCE OF INFLAMMATORY PAIN. METHODS: PERSISTENT INFLAMMATORY PAIN WAS INDUCED THROUGH THE INJECTION OF COMPLETE FREUND'S ADJUVANT (CFA) IN THE LEFT HIND PAW OF RATS. ACETYL-HISTONE H3 AND H4 LEVEL WAS DETERMINED BY CHROMATIN IMMUNOPRECIPITATION IN THE SPINAL DORSAL HORN. PAIN BEHAVIOUR AND INHIBITORY SYNAPTIC FUNCTION OF SPINAL CORD WERE DETERMINED BEFORE AND AFTER CFA INJECTION. KCC2 EXPRESSION WAS DETERMINED BY REAL TIME RT-PCR AND WESTERN BLOT. INTRATHECAL KCC2 SIRNA (2 MUG PER 10 MUL PER RAT) OR HDAC INHIBITOR (10 MUG PER 10 MUL PER RAT) WAS INJECTED ONCE DAILY FOR 3 DAYS BEFORE CFA INJECTION. RESULTS: PERSISTENT INFLAMMATORY PAIN EPIGENETICALLY SUPPRESSED KCC2 EXPRESSION THROUGH HISTONE DEACETYLASE (HDAC)-MEDIATED HISTONE HYPOACETYLATION, RESULTING IN DECREASED INHIBITORY SIGNALLING EFFICACY. KCC2 KNOCK-DOWN CAUSED BY INTRATHECAL ADMINISTRATION OF KCC2 SIRNA IN NAIVE RATS REDUCED KCC2 EXPRESSION IN THE SPINAL CORD, LEADING TO SENSITIZED PAIN BEHAVIOURS AND IMPAIRED INHIBITORY SYNAPTIC TRANSMISSION IN THEIR SPINAL CORDS. MOREOVER, INTRATHECAL HDAC INHIBITOR INJECTION IN CFA RATS INCREASED KCC2 EXPRESSION, PARTIALLY RESTORING THE SPINAL INHIBITORY SYNAPTIC TRANSMISSION AND RELIEVING THE SENSITIZED PAIN BEHAVIOUR. CONCLUSION: THESE FINDINGS SUGGEST THAT THE TRANSCRIPTION OF SPINAL KCC2 IS REGULATED BY HISTONE ACETYLATION EPIGENETICALLY FOLLOWING CFA. SIGNIFICANCE: PERSISTENT PAIN SUPPRESSES KCC2 EXPRESSION THROUGH HDAC-MEDIATED HISTONE HYPOACETYLATION AND CONSEQUENTLY IMPAIRS THE INHIBITORY FUNCTION OF INHIBITORY INTERNEURONS. DRUGS SUCH AS HDAC INHIBITORS THAT SUPPRESS THE INFLUENCES OF PERSISTENT PAIN ON THE EXPRESSION OF KCC2 MAY SERVE AS A NOVEL ANALGESIC. 2017 8 5459 15 RESEARCH ON THE EPIGENETIC REGULATION MECHANISM OF THE PTPN6 GENE IN ADVANCED CHRONIC MYELOID LEUKAEMIA. PTPN6, A TYROSINE PHOSPHATASE PROTEIN, PLAYS A NEGATIVE ROLE IN CELL SIGNAL TRANSDUCTION AND IS NEGATIVELY CORRELATED WITH TUMOUR FORMATION AND GROWTH. HOWEVER, EPIGENETIC REGULATION MECHANISM OF THE PTPN6 GENE IN ADVANCED CHRONIC MYELOID LEUKAEMIA (CML) REMAINS UNCLEAR. THIS STUDY INVESTIGATED BONE MARROW OR BLOOD SAMPLES FROM 44 CML PATIENTS AND 10 HEALTHY VOLUNTEERS. KCL22 AND K562 CELLS WERE CULTURED AND TREATED WITH DEMETHYLATION DRUGS AND HISTONE DEACETYLASE INHIBITORS. REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR), METHYLATION-SPECIFIC PCR, BISULFITE SEQUENCING PCR, WESTERN BLOTTING, CO-IMMUNOPRECIPITATION AND CHROMATIN IMMUNOPRECIPITATION (CHIP) WAS PERFORMED. PTPN6 WAS DOWN-REGULATED IN CELL LINES AND PATIENTS WITH ADVANCED PHASE CML, WHEREAS DNMT1, DNMT3A, MECP2, MBD2 AND HDAC1 WERE UP-REGULATED. TREATMENT WITH 5-AZACYTIDINE, DECITABINE, SODIUM VALPROATE AND LBH589 INCREASED PTPN6 EXPRESSION, BUT DECREASED THAT OF DNMT1, DNMT3A, MECP2, MBD2 AND HDAC1. IMMUNOPRECIPITATION AND MASS SPECTROMETRY SHOWED THAT HDAC1 COMBINED DIRECTLY WITH PTPN6. CHIP-SEQ SHOWED THAT HDAC1 DID NOT COMBINE WITH THE PROMOTER REGION OF PTPN6, WHILE MAPK, AKT, STAT5, JAK2 AND MYC PROMOTER REGIONS ALL COMBINED WITH HDAC1. PTPN6 IS ASSOCIATED WITH PROGRESSION OF CML. LOW EXPRESSION LEVEL OF PTPN6 WAS ASSOCIATED WITH DNA METHYLATION AND REGULATED BY HISTONE ACETYLATION. HDAC1 PARTICIPATES IN THE REGULATION OF PTPN6. 2017 9 5402 26 REDUCTION OF SIRT1-MEDIATED EPIGENETIC UPREGULATION OF NAV1.7 CONTRIBUTES TO OXALIPLATIN-INDUCED NEUROPATHIC PAIN. BACKGROUND: CLINICALLY, NEUROPATHIC PAIN IS A SEVERE SIDE EFFECT OF OXALIPLATIN CHEMOTHERAPY, WHICH USUALLY LEADS TO DOSE REDUCTION OR CESSATION OF TREATMENT. DUE TO THE UNAWARENESS OF DETAILED MECHANISMS OF OXALIPLATIN-INDUCED NEUROPATHIC PAIN, IT IS DIFFICULT TO DEVELOP AN EFFECTIVE THERAPY AND LIMITS ITS CLINICAL USE. OBJECTIVES: THE AIM OF THE PRESENT STUDY WAS TO IDENTIFY THE ROLE OF SIRTUIN 1 (SIRT1) REDUCTION IN EPIGENETIC REGULATION OF THE EXPRESSION OF VOLTAGE-GATED SODIUM CHANNELS 1.7 (NAV1.7) IN THE DORSAL ROOT GANGLION (DRG) DURING OXALIPLATIN-INDUCED NEUROPATHIC PAIN. STUDY DESIGN: CONTROLLED ANIMAL STUDY. SETTING: UNIVERSITY LABORATORY. METHODS: THE VON FREY TEST WAS PERFORMED TO EVALUATE PAIN BEHAVIOR IN RATS. REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION, WESTERN BLOTTING, ELECTROPHYSIOLOGICAL RECORDING, CHROMATIN IMMUNOPRECIPITATION, AND SMALL INTERFERING RNA (SIRNA) WERE USED TO ILLUSTRATE THE MECHANISMS. RESULTS: IN THE PRESENT STUDY, WE FOUND THAT BOTH THE ACTIVITY AND EXPRESSION OF SIRT1 WERE SIGNIFICANTLY DECREASED IN RAT DRG FOLLOWING OXALIPLATIN TREATMENT. THE ACTIVATOR OF SIRT1, RESVERATROL, NOT ONLY INCREASED THE ACTIVITY AND EXPRESSION OF SIRT1, BUT ALSO ATTENUATED THE MECHANICAL ALLODYNIA FOLLOWING OXALIPLATIN TREATMENT. IN ADDITION, LOCAL KNOCKDOWN OF SIRT1 BY INTRATHECAL INJECTION OF SIRT1 SIRNA CAUSED MECHANICAL ALLODYNIA IN NAIVE RATS. BESIDES, OXALIPLATIN TREATMENT ENHANCED THE ACTION POTENTIAL FIRING FREQUENCY OF DRG NEURONS AND THE EXPRESSION OF NAV1.7 IN DRG AND ACTIVATION OF SIRT1 BY RESVERATROL REVERSED THIS EFFECT. FURTHERMORE, BLOCKING NAV1.7 BY PROTX II (A SELECTIVE NAV1.7 CHANNEL BLOCKER) REVERSED OXALIPLATIN-INDUCED MECHANICAL ALLODYNIA. IN ADDITION, HISTONE H3 HYPERACETYLATION AT THE NAV1.7 PROMOTER IN DRG OF RATS FOLLOWING OXALIPLATIN TREATMENT WAS SIGNIFICANTLY SUPPRESSED BY ACTIVATION OF SIRT1 WITH RESVERATROL. MOREOVER, BOTH THE EXPRESSION OF NAV1.7 AND HISTONE H3 ACETYLATION AT THE NAV1.7 PROMOTER WERE UPREGULATED IN THE DRG BY LOCAL KNOCKDOWN OF SIRT1 WITH SIRT1 SIRNA IN NAIVE RATS. LIMITATIONS: MORE UNDERLYING MECHANISM(S) OF SIRT1 REDUCTION AFTER OXALIPLATIN TREATMENT NEEDS TO BE EXPLORED IN FUTURE RESEARCH. CONCLUSIONS: THESE FINDINGS SUGGEST THAT REDUCTION OF SIRT1-MEDIATED EPIGENETIC UPREGULATION OF NAV1.7 IN THE DRG CONTRIBUTES TO THE DEVELOPMENT OF OXALIPLATIN-INDUCED NEUROPATHIC PAIN IN RATS. THE INTRATHECAL DRUG DELIVERY TREATMENT OF ACTIVATING SIRT1 MIGHT BE A NOVEL THERAPEUTIC OPTION FOR OXALIPLATIN-INDUCED NEUROPATHIC PAIN. 2023 10 6231 16 THE LONG NONCODING RNA MEG3 AND ITS TARGET MIR-147 REGULATE JAK/STAT PATHWAY IN ADVANCED CHRONIC MYELOID LEUKEMIA. BACKGROUND: LONG NON-CODING (LNC) RNAS PLAYS AN IMPORTANT ROLE IN CHRONIC MYELOID LEUKEMIA (CML). IN THIS STUDY, WE AIMED TO UNCOVER THE MECHANISM OF THE LNCRNA MATERNALLY EXPRESSED 3 (MEG3) AND ITS TARGET MICRORNA-147 (MIR-147) IN CML. METHODS: SIXTY CML PATIENTS AND 10 HEALTHY DONORS WERE INCLUDED IN THE STUDY. THE METHYLATION OF MEG3 AND MIR-147 PROMOTER WAS DETERMINED BY METHYLATION-SPECIFIC PCR. THE RELATIONSHIP OF MEG3 AND MIR-147 WAS EXPLORED BY LUCIFERASE ASSAY. THE INTERACTIONS OF PROTEINS WERE STUDIED BY RNA PULL-DOWN ASSAY, RNA IMMUNOPRECIPITATION AND CO-IMMUNOPRECIPITATION. FINDINGS: PATIENTS IN ACCELERATED PHASE CML (CML-AP) AND BLAST PHASE CML (CML-BP) SHOWED LOWER EXPRESSIONS OF MEG3 AND MIR-147 AND HIGHER EXPRESSIONS OF DNMT1, DNMT3B, MBD2, MECP2 AND HDAC1 COMPARED TO THE CONTROLS. THESE PATIENTS ALSO SHOWED A HIGHER DEGREE OF METHYLATION OF MEG3 AND MIR-147 WHILE THERE WAS A REDUCTION AFTER CHIDAMIDE TREATMENT. FURTHERMORE, THE OVEREXPRESSION OF MEG3 AND MIR-147 INHIBITED CELL PROLIFERATION BOTH IN VIVO AND IN VITRO, PROMOTED APOPTOSIS AND DECREASED THE EXPRESSIONS OF DNMT1, DNMT3A, DNMT3B, MBD2, HDAC1 AND MECP2. WE ALSO FOUND MEG3 INTERACTED WITH DNMT1, JAK2, STAT3, HDAC1, AND TYK2, AND JAK2 WAS BOUND TO STAT3, STAT5 AND MYC. MORE INTERESTINGLY, JAK2 WAS BOUND TO TYK2 BY THE BRIDGE OF MEG3. INTERPRETATION: LNCRNA MEG3 AND ITS TARGET MIR-147 MAY SERVE AS A NOVEL THERAPEUTIC TARGET FOR CML BLAST CRISIS, AND CHIDAMIDE MIGHT HAVE A POTENTIAL CLINICAL APPLICATION IN TREATING CML BLAST CRISIS. 2018 11 4698 15 NFATC2-DEPENDENT EPIGENETIC DOWNREGULATION OF THE TSC2/BECLIN-1 PATHWAY IS INVOLVED IN NEUROPATHIC PAIN INDUCED BY OXALIPLATIN. NEUROPATHIC PAIN IS A COMMON DOSE-LIMITING SIDE EFFECT OF OXALIPLATIN, WHICH HAMPERS THE EFFECTIVE TREATMENT OF TUMORS. HERE, WE FOUND THAT UPREGULATION OF TRANSCRIPTION FACTOR NFATC2 DECREASED THE EXPRESSION OF BECLIN-1, A CRITICAL MOLECULE IN AUTOPHAGY, IN THE SPINAL DORSAL HORN, AND CONTRIBUTED TO NEUROPATHIC PAIN FOLLOWING OXALIPLATIN TREATMENT. MEANWHILE, MANIPULATING AUTOPHAGY LEVELS BY INTRATHECAL INJECTION OF RAPAMYCIN (RAPA) OR 3-METHYLADENINE (3-MA) DIFFERENTIALLY ALTERED MECHANICAL ALLODYNIA IN OXALIPLATIN-TREATED OR NAIVE RATS. UTILIZING CHROMATIN IMMUNOPRECIPITATION-SEQUENCING (CHIP-SEQ) ASSAY COMBINED WITH BIOINFORMATICS ANALYSIS, WE FOUND THAT NFATC2 NEGATIVELY REGULATED THE TRANSCRIPTION OF TUBEROUS SCLEROSIS COMPLEX PROTEIN 2 (TSC2), WHICH CONTRIBUTED TO THE OXALIPLATIN-INDUCED BECLIN-1 DOWNREGULATION. FURTHER ASSAYS REVEALED THAT NFATC2 REGULATED HISTONE H4 ACETYLATION AND METHYLATION IN THE TSC2 PROMOTER SITE 1 IN RATS' DORSAL HORNS WITH OXALIPLATIN TREATMENT. THESE RESULTS SUGGESTED THAT NFATC2 MEDIATED THE EPIGENETIC DOWNREGULATION OF THE TSC2/BECLIN-1 AUTOPHAGY PATHWAY AND CONTRIBUTED TO OXALIPLATIN-INDUCED MECHANICAL ALLODYNIA, WHICH PROVIDED A NEW THERAPEUTIC INSIGHT FOR CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN. 2023 12 1831 19 EFFECTS OF MATERNAL SEPARATION AND ANTIDEPRESSANT DRUG ON EPIGENETIC REGULATION OF THE BRAIN-DERIVED NEUROTROPHIC FACTOR EXON I PROMOTER IN THE ADULT RAT HIPPOCAMPUS. AIM: EARLY LIFE STRESS CAN INDUCE EPIGENETIC CHANGES THROUGH GENETIC AND ENVIRONMENTAL INTERACTIONS AND IS A RISK FACTOR FOR DEPRESSION. BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) HAS BEEN IMPLICATED IN THE PATHOPHYSIOLOGY OF DEPRESSION AND ANTIDEPRESSANT DRUG ACTION. WE INVESTIGATED EPIGENETIC CHANGES AT THE BDNF EXON I PROMOTER IN THE HIPPOCAMPUS OF ADULT RATS SUBJECTED TO MATERNAL SEPARATION (MS) DURING EARLY LIFE AND TREATED WITH AN ANTIDEPRESSANT DRUG AS ADULTS. METHODS: RAT PUPS WERE SUBJECTED TO MS FROM POSTNATAL DAY 1 TO 21 AND RECEIVED CHRONIC ESCITALOPRAM (ESC) AS ADULTS. WE ASSESSED THE EFFECTS OF MS AND ESC ON BDNF EXON I AND DNA METHYLTRANSFERASES (DNMT) MRNA LEVELS (QUANTITATIVE REVERSE-TRANSCRIPTION POLYMERASE CHAIN REACTION), ACETYLATED HISTONE H3, AND MECP2 BINDING TO THE BDNF PROMOTER I (CHROMATIN IMMUNOPRECIPITATION FOLLOWED BY REAL-TIME POLYMERASE CHAIN REACTION), AND BDNF PROTEIN LEVELS (ENZYME-LINKED IMMUNOSORBENT ASSAY). RESULTS: THE LEVELS OF BDNF PROTEIN, EXON I MRNA, HISTONE H3 ACETYLATION, AND DNMT1 AND DNMT3A MRNA WERE ALTERED IN THE MS GROUP COMPARED WITH THE CONTROL GROUP. SIGNIFICANT DECREASES WERE OBSERVED IN THE BDNF PROTEIN, EXON I MRNA, AND HISTONE H3 ACETYLATION LEVELS AND THERE WERE SIGNIFICANT INCREASES IN DNMT1 AND DNMT3A MRNA LEVELS. THE COMPARISON BETWEEN THE MS + ESC AND MS GROUPS REVEALED SIGNIFICANT INCREASES IN BDNF PROTEIN, EXON I MRNA, AND HISTONE H3 ACETYLATION LEVELS AND SIGNIFICANT DECREASES IN MECP2 AND DNMT1 AND DNMT3A MRNA LEVELS. CONCLUSION: THESE FINDINGS INDICATE THAT MS INDUCED EPIGENETIC CHANGES AT THE BDNF EXON I PROMOTER AND THESE CHANGES WERE PREVENTED BY ANTIDEPRESSANT DRUG TREATMENT DURING ADULTHOOD. 2018 13 1120 17 COMPARISON OF DIFFERENT HISTONE DEACETYLASE INHIBITORS IN ATTENUATING INFLAMMATORY PAIN IN RATS. HISTONE DEACETYLASE INHIBITORS (HDACIS), WHICH INTERFERE WITH THE EPIGENETIC PROCESS OF HISTONE ACETYLATION, HAVE SHOWN ANALGESIC EFFECTS IN ANIMAL MODELS OF PERSISTENT PAIN. THE HDAC FAMILY COMPRISES 18 GENES; HOWEVER, THE DIFFERENT EFFECTS OF DISTINCT CLASSES OF HDACIS ON PAIN RELIEF REMAIN UNCLEAR. THE AIM OF THIS STUDY WAS TO DETERMINE THE EFFICACY OF THESE HDACIS ON ATTENUATING THERMAL HYPERALGESIA IN PERSISTENT INFLAMMATORY PAIN. PERSISTENT INFLAMMATORY PAIN WAS INDUCED BY INJECTING COMPLETE FREUND'S ADJUVANT (CFA) INTO THE LEFT HIND PAW OF RATS. THEN, HDACIS TARGETING CLASS I (ENTINOSTAT (MS-275)) AND CLASS IIA (SODIUM BUTYRATE, VALPROIC ACID (VPA), AND 4-PHENYLBUTYRIC ACID (4-PBA)), OR CLASS II (SUBEROYLANILIDE HYDOXAMIC ACID (SAHA), TRICHOSTATIN A (TSA), AND DACINOSTAT (LAQ824)) WERE ADMINISTERED INTRAPERITONEALLY ONCE DAILY FOR 3 OR 4 DAYS. WE FOUND THAT THE INJECTION OF SAHA ONCE A DAY FOR 3 DAYS SIGNIFICANTLY ATTENUATED CFA-INDUCED THERMAL HYPERALGESIA FROM DAY 4 AND LASTED 7 DAYS. IN COMPARISON WITH SAHA, SUPPRESSION OF HYPERALGESIA BY 4-PBA PEAKED ON DAY 2, WHEREAS THAT BY MS-275 OCCURRED ON DAYS 5 AND 6. FATIGUE WAS A SERIOUS SIDE EFFECT SEEN WITH MS-275. THESE FINDINGS WILL BE BENEFICIAL FOR OPTIMIZING THE SELECTION OF SPECIFIC HDACIS IN MEDICAL FIELDS SUCH AS PAIN MEDICINE AND NEUROPSYCHIATRY. 2019 14 5458 16 RESEARCH ON EPIGENETIC MECHANISM OF SFRP2 IN ADVANCED CHRONIC MYELOID LEUKEMIA. SECRETED FRIZZLED-RELATED PROTEIN 2 (SFRP2) HAS BEEN REPORTED TO ACT AS A TUMOR SUPPRESSORS. THIS STUDY AIMS TO DETECT THE BIOLOGICAL ROLE OF SFRP2 IN ADVANCED CHRONIC MYELOID LEUKEMIA (CML). IN THIS STUDY WE EXAMINED BONE MARROW SAMPLES FROM 45 CML PATIENTS AND 10 HEALTHY DONORS. K562 AND KCL22 CELLS WERE CULTURED AND TREATED WITH DEMETHYLATION DRUG AND HISTONE DEACETYLASE INHIBITOR (HDACI). KCL22 AND K562 CELLS WERE TRANSFECTED WITH LENTIVIRAL VECTOR (LV)-SFRP2, LV-CONTROL. THE CELLS WERE THEN SUBJECTED TO PROLIFERATION AND APOPTOSIS ASSAYS, REAL TIME POLYMERASE CHAIN REACTION (PCR), METHYLATION-SPECIFIC PCR (MSP), WESTERN BLOTTING, CO-IMMUNOPRECIPITATION (COIP) AND CHROMATIN IMMUNOPRECIPITATION (CHIP), WE FOUND THAT SFRP2 WAS DOWN-REGULATED IN THE ACCELERATED AND BLAST PHASE OF CML, WHEREAS, THE LEVELS OF WNT1, WNT3 AND WNT5A WERE UP-REGULATED IN THE ACCELERATED AND BLAST PHASE OF CML. OVEREXPRESSION SFRP2 INHIBITED PROLIFERATION, PROMOTED APOPTOSIS AND ACTIVATED THE WNT PATHWAY. COIP-MS RESULTS SHOWED THAT SFRP2 INTERACTED WITH WNT1 AND WNT5A. CHIP-SEQ RESULT INDICATED THAT THE PROMOTER OF H3K4ME3 AND H3K27ME3 WERE ABLE TO INTERACT WITH SFRP2. IN CONCLUSION, OUR FINDINGS DEMONSTRATED THE SFRP2 ACT AS A POTENTIAL THERAPEUTIC TARGET FOR ADVANCED CML. FURTHERMORE, OUR RESULTS SUPPORT THE USE OF DEMETHYLATION DRUGS AND HDACI AS A POTENTIAL CML TREATMENT STRATEGY. 2018 15 6108 23 THE ENRICHED ENVIRONMENT AMELIORATES CHRONIC UNPREDICTABLE MILD STRESS-INDUCED DEPRESSIVE-LIKE BEHAVIORS AND COGNITIVE IMPAIRMENT BY ACTIVATING THE SIRT1/MIR-134 SIGNALING PATHWAY IN HIPPOCAMPUS. BACKGROUND: CHRONIC UNPREDICTABLE MILD STRESS (CUMS) IS AN IMPORTANT RISK FACTOR FOR DEPRESSION AND COGNITIVE DEFICITS IN HUMANS. ENRICHED ENVIRONMENT (EE) SHOWED A BENEFICIAL EFFECT ON DEPRESSION AND COGNITION BY ENHANCING BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) EXPRESSION AND SYNAPTIC PLASTICITY. HOWEVER, IT IS STILL NOT CLEARLY UNDERSTOOD WHETHER AN EPIGENETIC MECHANISM IS INVOLVED IN THE BDNF MODULATION AND SYNAPTIC PLASTICITY THAT OCCURS AFTER EE TREATMENT FOR THE DEPRESSIVE-LIKE BEHAVIORS AND COGNITIVE DEFICITS ELICITED BY CUMS. IN THIS STUDY, WE INVESTIGATED THE POSSIBLE MECHANISM OF THE NEUROPROTECTIVE EFFECT OF EE. METHODS: ALL RATS WERE EXPOSED TO THE 5-WEEK CUMS PROCEDURE EXCEPT THE CONTROL GROUP. AFTER CUMS PROCEDURE, SOME RATS WERE STEREOTAXICALLY INJECTED WITH SIRT1 PHARMACOLOGIC INHIBITOR EX527 OR SIRT1 KNOCKING DOWN LENTIVIRUS (SH-SIRT1) IN THE HIPPOCAMPUS FOLLOWED BY EE TREATMENT FOR 3 WEEKS. OTHER RATS WERE DIRECTLY SUBJECTED TO EE TREATMENT WITHOUT STEREOTAXIC INJECTION. BEHAVIORAL TESTS WERE USED TO APPRAISE DEPRESSION AND COGNITION AFTER EE TREATMENT. THEN EPIGENETIC MOLECULES, SYNAPTIC PROTEINS, DENDRITIC SPINE DENSITY AND BRANCHES, AND SYNAPTIC MORPHOLOGY OF THE DORSAL HIPPOCAMPUS WERE DETERMINED. RESULTS: WE FOUND THAT CUMS INDUCED DEPRESSIVE-LIKE BEHAVIORS INCLUDING DECREASED SUCROSE PREFERENCE RATIO, PROLONGED IMMOBILITY AND REDUCED LOCOMOTOR AND EXPLORATORY ACTIVITY; COGNITIVE DEFICITS INCLUDING SPATIAL LEARNING AND MEMORY IMPAIRMENT; REDUCED DENDRITIC SPINE DENSITY AND NUMBER OF BRANCHES; THINNED POSTSYNAPTIC DENSITY; DOWNREGULATED SIRT1/MICRORNA-134 PATHWAY, DECREASED BDNF AND SYNAPTIC PROTEINS INCLUDING SYNAPTOPHYSIN (SYN) AND POSTSYNAPTIC DENSITY PROTEIN 95 (PSD95) EXPRESSION IN THE HIPPOCAMPUS. HOWEVER, THE CUMS-INDUCED DEPRESSIVE-LIKE BEHAVIORS, COGNITIVE DEFICITS, DENDRITIC SPINE DENSITY AND BRANCH NUMBER REDUCTION, POSTSYNAPTIC DENSITY THINNING, SIRT1/MICRORNA-134 PATHWAY DOWNREGULATION, BDNF AND SYNAPTIC PROTEINS REDUCTION, INCLUDING SYNAPTOPHYSIN (SYN) AND POSTSYNAPTIC DENSITY PROTEIN 95 (PSD95), WERE REVERSED BY EE TREATMENT. HOWEVER, DEPRESSIVE-LIKE BEHAVIORS AND COGNITIVE DEFICITS WERE OBSERVED AGAIN IN RATS SUBJECTED TO STEREOTAXIC INJECTION WITH EX527 OR SH-SIRT1. FURTHERMORE, THIS STUDY ALSO FOUND THAT SIRT1/MICRORNA-134 REGULATES THE DOWNSTREAM MOLECULES BDNF, AND THE SYNAPTIC PROTEINS SYN AND PSD95 IN PRIMARY CULTURED HIPPOCAMPAL NEURONS. CONCLUSIONS: THIS STUDY PROVIDES EVIDENCE FOR THE NEUROPROTECTIVE ROLE OF EE ON DEPRESSION AND COGNITIVE DEFICITS BY ACTIVATING THE SIRT1/MICRORNA-134 PATHWAY, WHICH ACCOUNTS FOR THE REGULATION OF SYNAPTIC PROTEINS, INCLUDING BDNF, PSD95 AND SYN, DENDRITIC REMODELING AND ULTRASTRUCTURE CHANGES OF SYNAPSES IN THE HIPPOCAMPUS. 2019 16 3082 23 GENOME-WIDE REDISTRIBUTION OF MECP2 IN DORSAL ROOT GANGLIA AFTER PERIPHERAL NERVE INJURY. BACKGROUND: METHYL-CPG-BINDING PROTEIN 2 (MECP2), A PROTEIN WITH AFFINITY FOR METHYLATED CYTOSINES, IS CRUCIAL FOR NEURONAL DEVELOPMENT AND FUNCTION. MECP2 REGULATES GENE EXPRESSION THROUGH ACTIVATION, REPRESSION AND CHROMATIN REMODELING. MUTATIONS IN MECP2 CAUSE RETT SYNDROME, AND THESE PATIENTS DISPLAY IMPAIRED NOCICEPTION. WE OBSERVED AN INCREASE IN MECP2 EXPRESSION IN MOUSE DORSAL ROOT GANGLIA (DRG) AFTER PERIPHERAL NERVE INJURY. THE FUNCTIONAL IMPLICATION OF INCREASED MECP2 IS LARGELY UNKNOWN. TO IDENTIFY REGIONS OF THE GENOME BOUND BY MECP2 IN THE DRG AND THE CHANGES INDUCED BY NERVE INJURY, A CHROMATIN IMMUNOPRECIPITATION OF MECP2 FOLLOWED BY SEQUENCING (CHIP-SEQ) WAS PERFORMED 4 WEEKS AFTER SPARED NERVE INJURY (SNI). RESULTS: WHILE THE NUMBER OF BINDING SITES ACROSS THE GENOME REMAINED SIMILAR IN THE SNI MODEL AND SHAM CONTROL, SNI INDUCED THE REDISTRIBUTION OF MECP2 TO TRANSCRIPTIONALLY RELEVANT REGIONS. TO DETERMINE HOW DIFFERENTIAL BINDING OF MECP2 CAN AFFECT GENE EXPRESSION IN THE DRG, WE INVESTIGATED MMU-MIR-126, A MICRORNA LOCUS THAT HAD ENRICHED MECP2 BINDING IN THE SNI MODEL. ENRICHED MECP2 BINDING TO MIR-126 LOCUS AFTER NERVE INJURY REPRESSED MIR-126 EXPRESSION, AND THIS WAS NOT MEDIATED BY ALTERATIONS IN METHYLATION PATTERN AT THE MIR-126 LOCUS. DOWNREGULATION OF MIR-126 RESULTED IN THE UPREGULATION OF ITS TWO TARGET GENES DNMT1 AND VEGFA IN NEURO 2A CELLS AND IN SNI MODEL COMPARED TO CONTROL. THESE TARGET GENES WERE SIGNIFICANTLY DOWNREGULATED IN MECP2-NULL MICE COMPARED TO WILD-TYPE LITTERMATES, INDICATING A REGULATORY ROLE FOR MECP2 IN ACTIVATING DNMT1 AND VEGFA EXPRESSION. INTRATHECAL DELIVERY OF MIR-126 WAS NOT SUFFICIENT TO REVERSE NERVE INJURY-INDUCED MECHANICAL AND THERMAL HYPERSENSITIVITY, BUT DECREASED DNMT1 AND VEGFA EXPRESSION IN THE DRG. CONCLUSIONS: OUR STUDY SHOWS A REGULATORY ROLE FOR MECP2 IN THAT CHANGES IN GLOBAL REDISTRIBUTION CAN RESULT IN DIRECT AND INDIRECT MODULATION OF GENE EXPRESSION IN THE DRG. ALTERATIONS IN GENOME-WIDE BINDING OF MECP2 THEREFORE PROVIDE A MOLECULAR BASIS FOR A BETTER UNDERSTANDING OF EPIGENETIC REGULATION-INDUCED MOLECULAR CHANGES UNDERLYING NERVE INJURY. 2016 17 1813 20 EFFECTS OF CAFFEIC ACID ON EPIGENETICS IN THE BRAIN OF RATS WITH CHRONIC UNPREDICTABLE MILD STRESS. THE PRESENT STUDY HYPOTHESIZED THAT CAFFEIC ACID (3,4?DIHYDROXYCINNAMIC ACID; CAA) MAY EXERT ANTIDEPRESSANT?LIKE EFFECTS IN RATS WITH CHRONIC UNPREDICTABLE MILD STRESS VIA EPIGENETIC MECHANISMS, SUCH AS DNA METHYLATION AND HYDROXYMETHYLATION. THE CHRONIC UNPREDICTABLE MILD STRESS (CUMS) MODEL WAS USED TO ANALYZE THE EFFECTS OF CAA ON BEHAVIORAL PHENOTYPES, AND TO EVALUATE THE DISTRIBUTION OF 5?METHYLCYTOSINE (5MC) AND 5?HYDROXYMETHYLCYTOSINE (5HMC) IN THE HIPPOCAMPUS AND PREFRONTAL CORTEX USING IMMUNOHISTOCHEMISTRY AND IMMUNOFLUORESCENCE. MRNA LEVELS OF THE GENES ENCODING BRAIN?DERIVED NEUROTROPIC FACTOR (BDNF) AND CATECHOL?O?METHYLTRANSFERASE (COMT), AND KEY ENZYMES REGULATING DNA METHYLATION [DNA METHYLTRANSFERASE (DNMT)1 AND DNMT3A] AND HYDROXYMETHYLATION [TEN?ELEVEN TRANSLOCATION (TET)1?3] WERE EXAMINED USING QUANTITATIVE (Q)PCR. FURTHERMORE, ENRICHMENT OF 5MC AND 5HMC AT THE PROMOTOR REGIONS OF THE BDNF AND COMT GENES WAS QUANTIFIED USING CHROMATIN IMMUNOPRECIPITATION?QPCR. BEHAVIORAL DATA SHOWED THAT CAA EXERTED A SLIGHT ANTIDEPRESSANT?LIKE EFFECT. BDNF AND COMT GENES SHOWED DIFFERENTIAL EXPRESSION PATTERNS DUE TO CUMS. CAA INTERVENTION INDUCED DIFFERENT DNMT1/DNMT3A AND TET1/TET2 MRNA LEVELS IN THE HIPPOCAMPUS AND PREFRONTAL CORTEX, RESPECTIVELY. CAA REGULATED THE RATIO OF 5MC/5HMC AT THE PROMOTOR REGION OF THE BDNF AND COMT GENES AND THEREFORE INFLUENCED GENE EXPRESSION, WHICH MAY BE A VALUABLE THERAPEUTIC OPTION FOR MAJOR DEPRESSIVE DISORDER (MDD). IN CONCLUSION, THERE WERE EPIGENETIC CHANGES IN THE HIPPOCAMPUS AND PREFRONTAL CORTEX IN CUMS RATS, AND CAA MAY FUNCTION AS A MODULATOR OF DNA METHYLATION TO REGULATE GENE TRANSCRIPTION, THUS PROVIDING A MECHANISTIC BASIS FOR THE USE OF THIS PHYTOCHEMICAL AGENT IN THE TREATMENT OF MDD. 2020 18 3721 23 INHIBITION OF CLASS II HISTONE DEACETYLASES IN THE SPINAL CORD ATTENUATES INFLAMMATORY HYPERALGESIA. BACKGROUND: SEVERAL CLASSES OF HISTONE DEACETYLASES (HDACS) ARE EXPRESSED IN THE SPINAL CORD THAT IS A CRITICAL STRUCTURE OF THE NOCICEPTIVE PATHWAY. HDAC-REGULATED HISTONE ACETYLATION IS AN IMPORTANT COMPONENT OF CHROMATIN REMODELING LEADING TO EPIGENETIC REGULATION OF GENE TRANSCRIPTION. TO UNDERSTAND THE ROLE OF HISTONE ACETYLATION IN EPIGENETIC REGULATION OF PATHOLOGICAL PAIN, WE HAVE STUDIED THE IMPACT OF DIFFERENT CLASSES OF HDACS IN THE SPINAL CORD ON INFLAMMATORY HYPERALGESIA INDUCED BY COMPLETE FREUND'S ADJUVANT (CFA). RESULTS: WE INTRATHECALLY APPLIED INHIBITORS SPECIFIC TO DIFFERENT CLASSES OF HDACS AND EVALUATED THEIR IMPACT ON INFLAMMATORY HYPERALGESIA. PRE-INJECTED INHIBITORS TARGETING CLASS I AS WELL AS II (SAHA, TSA, LAQ824) OR IIA (VPA, 4-PB) HDACS SIGNIFICANTLY DELAYED THE THERMAL HYPERALGESIA INDUCED BY UNILATERAL CFA INJECTION IN THE HINDPAW. EXISTING HYPERALGESIA INDUCED BY CFA WAS ALSO ATTENUATED BY THE HDAC INHIBITORS (HDACIS). IN CONTRAST, THESE INHIBITORS DID NOT INTERFERE WITH THE THERMAL RESPONSE EITHER IN NAIVE ANIMALS, OR ON THE CONTRALATERAL SIDE OF INFLAMED ANIMALS. INTERESTINGLY, MS-275 THAT SPECIFICALLY INHIBITS CLASS I HDACS FAILED TO ALTER THE HYPERALGESIA ALTHOUGH IT INCREASED HISTONE 3 ACETYLATION IN THE SPINAL CORD AS SAHA DID. USING IMMUNOBLOT ANALYSIS, WE FURTHER FOUND THAT THE LEVELS OF CLASS IIA HDAC MEMBERS (HDAC4, 5, 7, 9) IN THE SPINAL DORSAL HORN WERE UPREGULATED FOLLOWING CFA INJECTION WHILE THOSE OF CLASS I HDAC MEMBERS (HDAC1, 2, 3) REMAINED STABLE OR WERE SLIGHTLY REDUCED. CONCLUSIONS: OUR DATA SUGGEST THAT ACTIVITY OF CLASS II HDACS IN THE SPINAL CORD IS CRITICAL TO THE INDUCTION AND MAINTENANCE OF INFLAMMATORY HYPERALGESIA INDUCED BY CFA, WHILE ACTIVITY OF CLASS I HDACS MAY BE UNNECESSARY. COMPARISON OF THE EFFECTS OF HDACIS SPECIFIC TO CLASS II AND IIA AS WELL AS THE EXPRESSION PATTERN OF DIFFERENT HDACS IN THE SPINAL CORD IN RESPONSE TO CFA SUGGESTS THAT THE MEMBERS OF CLASS IIA HDACS MAY BE POTENTIAL TARGETS FOR ATTENUATING PERSISTENT INFLAMMATORY PAIN. 2010 19 3877 15 KDM6A PROMOTES IMATINIB RESISTANCE THROUGH YY1-MEDIATED TRANSCRIPTIONAL UPREGULATION OF TRKA INDEPENDENTLY OF ITS DEMETHYLASE ACTIVITY IN CHRONIC MYELOGENOUS LEUKEMIA. RATIONALE: DESPITE LANDMARK THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH TYROSINE KINASE INHIBITORS (TKIS), DRUG RESISTANCE REMAINS PROBLEMATIC. CANCER PATHOGENESIS INVOLVES EPIGENETIC DYSREGULATION AND IN PARTICULAR, HISTONE LYSINE DEMETHYLASES (KDMS) HAVE BEEN IMPLICATED IN TKI RESISTANCE. WE SOUGHT TO IDENTIFY KDMS WITH ALTERED EXPRESSION IN CML AND DEFINE THEIR CONTRIBUTION TO IMATINIB RESISTANCE. METHODS: BIOINFORMATICS SCREENING COMPARED KDM EXPRESSION IN CML VERSUS NORMAL BONE MARROW WITH SHRNA KNOCKDOWN AND FLOW CYTOMETRY USED TO MEASURE EFFECTS ON IMATINIB-INDUCED APOPTOSIS IN K562 CELLS. TRANSCRIPTOMIC ANALYSES WERE PERFORMED AGAINST KDM6A CRISPR KNOCKOUT/SHRNA KNOCKDOWN K562 CELLS ALONG WITH GENE RESCUE EXPERIMENTS USING WILDTYPE AND MUTANT DEMETHYLASE-DEAD KDM6A CONSTRUCTS. CO-IMMUNOPRECIPITATION, LUCIFERASE REPORTER AND CHIP WERE EMPLOYED TO ELUCIDATE MECHANISMS OF KDM6A-DEPENDENT RESISTANCE. RESULTS: AMONGST FIVE KDMS UPREGULATED IN CML, ONLY KDM6A DEPLETION SENSITIZED CML CELLS TO IMATINIB-INDUCED APOPTOSIS. RE-INTRODUCTION OF DEMETHYLASE-DEAD KDM6A AS WELL AS WILD-TYPE KDM6A RESTORED IMATINIB RESISTANCE. RNA-SEQ IDENTIFIED NTRK1 GENE DOWNREGULATION AFTER DEPLETION OF KDM6A. MOREOVER, NTRK1 EXPRESSION POSITIVELY CORRELATED WITH KDM6A IN A SUBSET OF CLINICAL CML SAMPLES AND KDM6A KNOCKDOWN IN FRESH CML ISOLATES DECREASED NTRK1 ENCODED PROTEIN (TRKA) EXPRESSION. MECHANISTICALLY, KDM6A WAS RECRUITED TO THE NTRK1 PROMOTER BY THE TRANSCRIPTION FACTOR YY1 WITH SUBSEQUENT TRKA UPREGULATION ACTIVATING DOWN-STREAM SURVIVAL PATHWAYS TO INVOKE IMATINIB RESISTANCE. CONCLUSION: CONTRARY TO ITS REPORTED ROLE AS A TUMOR SUPPRESSOR AND INDEPENDENT OF ITS DEMETHYLASE FUNCTION, KDM6A PROMOTES IMATINIB-RESISTANCE IN CML CELLS. THE IDENTIFICATION OF THE KDM6A/YY1/TRKA AXIS AS A NOVEL IMATINIB-RESISTANCE MECHANISM REPRESENTS AN UNEXPLORED AVENUE TO OVERCOME TKI RESISTANCE IN CML. 2021 20 2197 17 EPIGENETIC MODIFICATION OF BDNF MEDIATES NEUROPATHIC PAIN VIA MIR-30A-3P/EP300 AXIS IN CCI RATS. RECENT INVESTIGATION OF MICRORNAS ON CHRONIC PAIN HAS DEVELOPED A BREAKTHROUGH IN NEUROPATHIC PAIN MANAGEMENT. IN THE PRESENT STUDY, DECREASED EXPRESSION OF MIR-30A-3P WAS REPORTED USING QRT-PCR ANALYSIS AND LOSS OF MIR-30A-3P PROMOTED NEUROPATHIC PAIN PROGRESSION IN SCIATIC NERVE CHRONIC CONSTRICTIVE INJURY RATS THROUGH DETERMINING THE PAIN THRESHOLD. WE PREDICTED MIR-30A-3P COULD TARGET E-CADHERIN TRANSCRIPTIONAL ACTIVATOR (EP300) VIA BIOINFORMATICS ANALYSIS. MEANWHILE, WE FOUND THAT BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) IS INVOLVED IN NEUROPATHIC PAIN. HERE, WE EXHIBITED THAT EP300 EPIGENETICALLY UP-REGULATED BDNF VIA ENHANCING ACETYLATED HISTONE H3 AND H4 ON THE PROMOTER. FOR ANOTHER, MIR-30A-3P WAS ABLE TO MODIFY THE LEVEL OF BDNF AND ACETYLATED HISTONE H3 AND H4. LOSS OF MIR-30A-3P ENHANCED EP300 AND BDNF COLOCALIZATION IN CCI RATS. SUBSEQUENTLY, IT WAS SHOWN THAT INCREASED EP300 INDUCED NEUROPATHIC PAIN BY AN ENHANCEMENT OF NEURONAL BDNF LEVEL IN VIVO. TO SUM UP, IT WAS REVEALED THAT EPIGENETIC MODIFICATION OF BDNF PROMOTED NEUROPATHIC PAIN VIA EP300 INDUCED BY MIR-30A-3P IN CCI RATS. 2020